Elsevier and the Society of Hospital Medicine announce joint initiative aimed at helping patients with underlying substance use disorders

Elsevier, a global leader in evidence-based clinical practice content, research publishing and information analytics, today announced that it will partner with the Society of Hospital Medicine (SHM) in the development of materials to help hospitalists at the point-of-care with the identification, inpatient management, and discharge planning of patients with underlying substance use disorders (SUD). More than 17 million U.S. adults are affected by SUD and its underlying health conditions.

As part of this initiative, Elsevier has provided grant support to enable the Society of Hospital Medicine to develop a suite of tools and resources for hospitalists that will help them in identifying patients with SUD, initiating medications for opioid use disorder (MOUD) in the hospital setting, and supporting patient discharge to the home or community. Faculty working on the project have access to evidence-based information through Elsevier’s ClinicalKey® to inform their research. At project completion, SHM will contribute to the creation of point-of-care recommendations on the topic within ClinicalKey, allowing ClinicalKey users to quickly access the information, while reinforcing best practices recommended by SHM.

“Hospitalization represents an important step in identifying and treating patients with SUD,” said Josh Schoeller, President, Clinical Solutions, Elsevier. “It’s imperative to support hospitalists in acquiring the knowledge, evidence-based strategies and tools to effectively manage this patient population and address the growing health crisis in our country.”

The first output of this project, due to release this year, will be a discussion guide to support hospitalists in conducting patient-centered discussions with individuals who have a diagnosis of SUD with a focus on Opioid Use Disorder (OUD) including best practices and clinical scenarios in a case study format which review how to identify patients with OUD, initiate treatment and facilitate effective transitions of care strategies.

“We’re pleased to collaborate with Elsevier on this important initiative that we believe will have an impact in the health and wellbeing of many Americans suffering from substance use disorders,” said Jenna Goldstein, Director of SHM’s Center for Quality Improvement.

---

Notes for editors

About the Society of Hospital Medicine

Representing the fastest growing specialty in modern healthcare, the Society of Hospital Medicine (SHM) is celebrating 25 years as the leading medical society for hospitalists and their patients. SHM is dedicated to promoting the highest quality care for all hospitalized patients and overall excellence in the practice of hospital medicine through quality improvement, education, advocacy, and research. Over the past decade, studies have shown that hospitalists can contribute to decreased patient lengths of stay, reductions in hospital costs and readmission rates, and increased patient satisfaction. For more information about SHM and hospital medicine, visit hospitalmedicine.orgopens in new tab/window.

エルゼビアについて

エルゼビアは、先端情報と意思決定を支援しています。1世紀以上にわたり、人類の進歩のため先端科学とヘルスケアの進歩に貢献してきました。私たちは、170か国にわたるアカデミアや企業の研究コミュニティ、医師、看護師、未来の医療従事者、教育者の皆さまの重要な活動をサポートしています。これは、信頼できるエビデンスに基づく科学・医療コンテンツと高度なAI技術を組み合わせた革新的なソリューションにより知見の集積や重要な意思決定を支援することで実現しています。また、私たちは、これらの価値を製品や企業文化に組み込み、コミュニティとの協働を通じて、インクルージョンと持続可能性を推進しています。エルゼビア財団opens in new tab/windowは、世界中の研究と医療のパートナーシップを支援しています。

エルゼビアは、専門家およびビジネス向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Groupopens in new tab/windowの一事業を担っています。詳細につきましては、www.elsevier.comまたはソーシャルメディア@Elsevier Connectをご覧ください。